Why amg detection?

Accuracy

With an input correlated only to epileptic seizures, false positives will no longer be an issue as seen with many current detection solutions.

› Learn More About the Technology

Innovation

First device to combine novel gas sensing with vital-sign analysis for not only seizure forecasting, but seizure type determination as well for individuals who experience multiple types of seizures.

› Learn More About The Technology

Expertise

Developed by Ashley Galanti, PhD candidate in biomedical engineering, in collaboration with leading engineering and epilepsy specialists.

› Meet the Team

Mission-Driven

Built from personal passion and scientific rigor to make a real difference.

› Meet the Team

Our Mission

At AMG, we’re on a mission to empower people with epilepsy to reclaim independence and confidence. By detecting subtle chemical and physiological signals that precede a seizure, our wearable alerts you before it happens—so you can prepare, pause, and protect yourself or your loved one.

Current timeline

Since our founding in November 2022, AMG Detection has advanced from proof-of-concept prototypes to the doorstep of clinical validation. After completing sensor fabrication and chemistry, along with on-device AI in progress, we will soon be launching pre-clinical studies in real hospital settings.

2026

Prototype Ready
Finalize wearable package with integrated sensors & on-board AI

Pre-Clinical Study
Launch EMU trial with clinical partners to test the sensor functionality

Device Data Analysis & Refinement
Analyze interim and end-of-study accuracy, sensitivity, and selectivity data to fine-tune sensor algorithms, power management, and hardware performance for larger cohorts

2027

Final Form Factor

Device miniaturization and vital sensor integration for clinical study

Phase 1 Trial
Conduct multi-site study in the US and Europe to assess safety, usability, and seizure-prediction performance

Regulatory Filing

Submit to FDA’s Neurodiagnostic Devices division and file EU MDR Technical File with a Notified Body to pursue CE marking and enable U.S. and European market entry

2028

Go-to-Market
Finalize commercial-scale manufacturing with supplier and manufacturing relationships established, distribution partnerships, clinician training, and user support materials